Moffitt researchers identify how cancer cells adapt to survive harsh tumor microenvironments
(H. Lee Moffitt Cancer Center& Research Institute) To better understand the conditions that select for the Warburg Effect and the mechanisms where cells can express this metabolic adaptation, Moffitt researchers subjected nonmalignant cells to the harsh tumor microenvironment that is present during early carcinogenesis, known as ductal carcinoma in situ. In a new research article published in the Proceedings of the National Academy of Sciences, the Moffitt team shows that these conditions select for cells to express a Warburg Effect. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 19, 2021 Category: Cancer & Oncology Source Type: news

What Are Potential Problems of Congenital Lung Malformations?
Discussion Congenital lung malformations (CLM) are commonly identified with prenatal ultrasound and occur in ~1:2400 live births. The natural history shows that lesions may remain the same, enlarge or appear to disappear. There is a wide-range of clinical manifestations. Patients may be asymptomatic or symptomatic at birth and often develop symptoms later. The overall natural history is difficult to ascertain as there are fewer studies done in older children and adults. Those that are done often lack a good denominator by which to judge the incidence or prevalence. Resection is carried out usually if a patient is symptomat...
Source: PediatricEducation.org - January 18, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer ’s 2020 World Conference on Lung Cancer
January 12, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that eight company-sponsored presentations, including two oral presentations, will be featured at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore taking place virtually January 28-31, 2021. The presentations include updated data from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab in patients with NSCLC and EGFR exon 20 insertion mutations and two studies that characterize the high unmet need and lack of stand...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Skin cancer: Main symptoms to look out for warning of basal cell carcinoma
SKIN cancer is not only a condition one needs to worry about in the summertime. What are the main symptoms to look out for in basal cell carcinoma? (Source: Daily Express - Health)
Source: Daily Express - Health - January 12, 2021 Category: Consumer Health News Source Type: news

Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Media News)
Source: Roche Media News - January 12, 2021 Category: Pharmaceuticals Source Type: news

Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - January 12, 2021 Category: Pharmaceuticals Source Type: news

Oncotarget: PD-1/PD-L1 expression in anal squamous intraepithelial lesions
(Impact Journals LLC) Dr. Margot Bucau from The H ô pital Bichat-Claude Bernard said, " Anal intraepithelial neoplasia (AIN) is the precursor lesion for anal squamous cell carcinomas (ASCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2021 Category: International Medicine & Public Health Source Type: news

Proteogenomics offers insight to treating head and neck squamous cell carcinoma
(Baylor College of Medicine) A new study identifies three molecular subtypes in head and neck squamous cell carcinoma (HNSCC) that could be used to better determine appropriate treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 7, 2021 Category: International Medicine & Public Health Source Type: news

Leaps-Bayer-leads-USD-million-Series-B-financing-Senti-Bio-develop-next-generation-therapies-using
Senti Bio’s gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas / Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma (Source: Bayer Company News)
Source: Bayer Company News - January 6, 2021 Category: Pharmaceuticals Source Type: news

Liver cancer cells manipulate stromal cells involved in fibrosis to promote tumor growth
(Osaka University) Researchers led by Osaka University have found that liver cancer cells induce autophagy in hepatic stellate cells, causing them to produce a growth factor called GDF15 that promotes tumor growth. GDF15 was more highly expressed in tumor tissue than normal liver tissue, and patients with higher levels of GDF15 had a poorer prognosis. New therapies targeting GDF15 may help prevent the development and proliferation of hepatocellular carcinoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 6, 2021 Category: International Medicine & Public Health Source Type: news

Survival Rate for Hepatocellular Carcinoma
What Is the Survival Rate for Hepatocellular Carcinoma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 5, 2021 Category: General Medicine Source Type: news

How Serious Is Invasive Ductal Carcinoma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 5, 2021 Category: General Medicine Source Type: news

Researchers aim AI at rising oral cancers with $3.3M grant from National Cancer Institute
(Case Western Reserve University) Researchers at Case Western Reserve University and partners in the United States and India are applying artificial intelligence (AI) to help physicians customize treatments for patients with the most common oral cancer, known as squamous cell carcinomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 5, 2021 Category: Cancer & Oncology Source Type: news

Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer
Understanding the mechanisms of the Warburg shift to aerobic glycolysis is critical to defining the metabolic basis of cancer. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an aggressive cancer characterized by biallelic inactivation of the gene encoding the Krebs cycle enzyme fumarate hydratase, an early shift to aerobic glycolysis, and rapid metastasis. We observed impairment of the mitochondrial respiratory chain in tumors from patients with HLRCC. Biochemical and transcriptomic analyses revealed that respiratory chain dysfunction in the tumors was due to loss of expression of mitochondrial DNA (mtDNA)&n...
Source: Signal Transduction Knowledge Environment - January 5, 2021 Category: Science Authors: Crooks, D. R., Maio, N., Lang, M., Ricketts, C. J., Vocke, C. D., Gurram, S., Turan, S., Kim, Y.-Y., Cawthon, G. M., Sohelian, F., De Val, N., Pfeiffer, R. M., Jailwala, P., Tandon, M., Tran, B., Fan, T. W.- M., Lane, A. N., Ried, T., Wangsa, D., Malayeri Tags: STKE Research Articles Source Type: news

Peninsula biotech Calithera cuts a third of jobs after kidney cancer trial flop
Calithera Biosciences Inc. shed nearly half of its value and will cut about 30 jobs after a mid-stage clinical trial of its marquee drug failed in kidney cancer patients. The South San Francisco company (NASDAQ: CALA) said the job cuts represent 35% of its workforce. The bulk of the job losses would be among those prepping for a potential commercial launch of the drug, called telaglenastat or CB-839. The company's 444-person Phase II study found that advanced or m etastatic renal cell carcinoma… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 4, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Peninsula biotech Calithera cuts a third of jobs after kidney cancer trial flop
Calithera Biosciences Inc. shed nearly half of its value and will cut about 30 jobs after a mid-stage clinical trial of its marquee drug failed in kidney cancer patients. The South San Francisco company (NASDAQ: CALA) said the job cuts represent 35% of its workforce. The bulk of the job losses would be among those prepping for a potential commercial launch of the drug, called telaglenastat or CB-839. The company's 444-person Phase II study found that advanced or m etastatic renal cell carcinoma… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 4, 2021 Category: American Health Authors: Ron Leuty Source Type: news

Single-cell analysis of metastatic gastric cancer finds diverse tumor cell populations associated with patient outcomes
(University of Texas M. D. Anderson Cancer Center) Researchers from The University of Texas MD Anderson Cancer Center who profiled more than 45,000 individual cells from patients with peritoneal carcinomatosis (PC), a specific form of metastatic gastric cancer, defined the extensive cellular heterogeneity and identified two distinct subtypes correlated with patient survival. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 4, 2021 Category: International Medicine & Public Health Source Type: news

Pembrolizumab not cost effective in BCG-unresponsive bladder carcinoma in situ
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2021 Category: Drugs & Pharmacology Source Type: news

Skin cancer symptoms: Five warning signs of a basal cell carcinoma
SKIN CANCER can successfully be removed, without complications, with early detection and treatment. There are five warning signs of basal cell carcinoma. What are they? (Source: Daily Express - Health)
Source: Daily Express - Health - December 30, 2020 Category: Consumer Health News Source Type: news

Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
SAN MATEO, Calif., Dec. 23, 2020 -- (Healthcare Sales & Marketing Network) -- Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 ... Biopharmaceuticals, Oncology Rakuten Medical, photoimmunotherapy, Illuminox (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 23, 2020 Category: Pharmaceuticals Source Type: news

Fibroscan Liver Stiffness After Anti-viral Treatment for HCV Fibroscan Liver Stiffness After Anti-viral Treatment for HCV
This study investigated whether liver stiffness pre- or post-anti-viral therapy is associated with the development of decompensated cirrhosis, hepatocellular carcinoma, or death.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 16, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

BAVENCIO(R) (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
ROCKLAND, Mass. and NEW YORK, Dec. 11, 2020 -- (Healthcare Sales & Marketing Network) -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the Committee for ... Biopharmaceuticals, Oncology, Regulatory EMD Serono, Merck KGaA, BAVENCIO, avelumab, Urothelial Carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2020 Category: Pharmaceuticals Source Type: news

Uniquely human gene may drive numerous cancers
(Wiley) A new study published in FASEB BioAdvances reveals a human-specific connection between advanced carcinomas and a gene called SIGLEC12. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 9, 2020 Category: International Medicine & Public Health Source Type: news

New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with ...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized ...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Systemic Therapy for Non-Serous Ovarian Carcinoma Systemic Therapy for Non-Serous Ovarian Carcinoma
The treatment of non-serous ovarian cancer requires a different approach. What are the available therapeutic options?Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 4, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RARITAN, N.J., December 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. The application marks the first-ever regulatory submission for the treatment of patients with NSCLC with EGFR exon 20 insertion mutations.[1] The Company...
Source: Johnson and Johnson - December 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Rate of Cancer in Teens, Young Adults Increased From 1973 to 2015
Greatest rate of increase seen for kidney carcinoma in male, female adolescents and young adults (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 2, 2020 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Oncology, Pediatrics, Journal, Source Type: news

New treatment options for those with liver cancer
Sharon Silverman loves to travel. But after doctors in her hometown of Pensacola, Florida, diagnosed her with hepatocellular carcinoma and told her there were no treatment options, Sharon knew she had to take one more trip. Her destination: Mayo Clinic -- where a unique radiation procedure opened the door to future adventures. Reporter DeeDee Stiepan [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 2, 2020 Category: Databases & Libraries Source Type: news

Combination therapy might improve outcomes in treatment-resistant liver cancer
(Massachusetts General Hospital) A combination cancer therapy that is effective against treatment-resistant hepatocellular carcinoma (HCC) by inhibiting tumor growth and increasing survival has been identified by researchers at Massachusetts General Hospital. The dual therapy -- which combines the multikinase inhibitor drug regorafenib to " reprogram " the tumor immune microenvironment, and programmed cell death 1 antibodies to stimulate anti-tumor immunity -- improved survival in mouse models of HCC beyond what each therapy could have achieved alone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 30, 2020 Category: Cancer & Oncology Source Type: news

Patients Cured of HCV Still at High Liver Cancer Risk Patients Cured of HCV Still at High Liver Cancer Risk
The burden of hepatocellular carcinoma (HCC) appears likely to move from patients who currently have hepatitis C virus (HCV) infection to those who have previously been cured, a new modeling study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Pigment Traits, Sun Sensitivity Tied to Risk for Blood Cancers Pigment Traits, Sun Sensitivity Tied to Risk for Blood Cancers
Risk factors for keratinocyte carcinomas were associated with the risk of developing non-Hodgkin lymphomas and chronic lymphocytic leukemia in an analysis of 92,097 women.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 25, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Rural, Urban Disparities Seen for New Liver Cancer Cases
TUESDAY, Nov. 24, 2020 -- Rates of hepatocellular carcinoma (HCC) have slowed in urban areas but continue to increase in rural areas, particularly among Black and Hispanic residents, according to a study presented at The Liver Meeting, the annual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 24, 2020 Category: Pharmaceuticals Source Type: news

Epidemiology, Clinical Presentation, and Evaluation of UTUC Epidemiology, Clinical Presentation, and Evaluation of UTUC
What do we currently know about the epidemiology, presentation, and assessment of upper-tract urothelial carcinoma?Translational Andrology and Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 23, 2020 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Scientists regenerate skin with stem cells to see how DNA defects in kids cause cancer
(Cincinnati Children's Hospital Medical Center) Physicians and scientists at Cincinnati Children's Hospital Medical Center used new stem cell technology to regenerate and study living patient-specific skin in the lab, giving them a precise close up view of how inherited DNA defects cause skin damage and deadly squamous cell carcinoma in children and young adults with Fanconi anemia (FA). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 23, 2020 Category: Cancer & Oncology Source Type: news

Aspirin and Statins in Chronic Hepatitis B: It's Complicated Aspirin and Statins in Chronic Hepatitis B: It's Complicated
Statins play a bigger part than aspirin in reducing risk for hepatocellular carcinoma in patients with hepatitis B, new research shows, and cirrhosis seems to cancel any beneficial effect of aspirin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 19, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Interventions for basal cell carcinoma of the skin
Why is this question important?Basal cell carcinoma (BCC) is the most common form of skin cancer among people with white skin.BCC is not usually life ‐threatening but if left untreated, it can cause important disfigurement, especially on the face.Surgical removal of the affected area and surrounding skin is usually the first option for treating BCC. Several different surgical approaches exist as well as non ‐surgical treatments, such as radiotherapy (high doses of radiation that kill cancer cells), and anti‐cancer creams, gels and ointments.We reviewed the evidence from research studies, to find out which treatments ...
Source: Cochrane News and Events - November 18, 2020 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Positive Data Presented on Helio Health Liver Test for the Detection of Hepatocellular Carcinoma (HCC) Advances Product Development
New data demonstrate high accuracy of blood-based cfDNA methylation test for the detection of HCC Test has potential to outperform current screening modalities for early stage HCC within high risk populations IRVINE, Calif., Nov. 13, 2020 -- (Healthc... Diagnostics, Oncology Helio Health, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2020 Category: Pharmaceuticals Source Type: news

EGF promotes DKK1 transcription in hepatocellular carcinoma by enhancing the phosphorylation and acetylation of histone H3
The protein Dickkopf-1 (DKK1) is frequently overexpressed at the transcript level in hepatocellular carcinoma (HCC) and promotes metastatic progression through the induction of β-catenin, a Wnt signaling effector. We investigated how DKK1 expression is induced in HCC and found that activation of the epidermal growth factor receptor (EGFR) promoted parallel MEK-ERK and PI3K-Akt pathway signaling that converged to epigenetically stimulate DKK1 transcription. In HCC cell lines stimulated with EGF, EGFR-activated ERK phosphorylated the kinase PKM2 at Ser37, which promoted its nuclear translocation. Also in these cells, EG...
Source: Signal Transduction Knowledge Environment - November 10, 2020 Category: Science Authors: Niu, J., Li, W., Liang, C., Wang, X., Yao, X., Yang, R.-H., Zhang, Z.-S., Liu, H.-F., Liu, F.-Y., Pei, S.-H., Li, W.-Q., Sun, H., Fang, D., Xie, S.-Q. Tags: STKE Research Articles Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Oncotarget: Heterogeneity of CEACAM5 in breast cancer
(Impact Journals LLC) Oncotarget recently published " Heterogeneity of CEACAM5 in breast cancer " which reported that Here, we examined a repository of 110 cryopreserved primary breast carcinomas by immunohistochemistry to assess the distribution of CEACAM5 in tumor subtypes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 3, 2020 Category: International Medicine & Public Health Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Investor Update - October 29, 2020 Category: Pharmaceuticals Source Type: news

Rurality, Income Impact Stage at Diagnosis, Mortality in Liver Cancer
MONDAY, Oct. 26, 2020 -- Patients with hepatocellular carcinoma (HCC) from rural regions and lower-income households are more likely to have advanced-stage HCC at diagnosis and higher HCC mortality, according to a study published online Oct. 26 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 26, 2020 Category: Pharmaceuticals Source Type: news

Gene Signature May Be Similarly Prognostic in ILC and IDC Gene Signature May Be Similarly Prognostic in ILC and IDC
The MammaPrint 70-gene signature has similar prognostic performance in women with early-stage invasive lobular carcinoma and invasive ductal carcinoma (IDC), according to an exploratory analysis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 20, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Icotinib Plus Radiotherapy Ups Survival in Elderly With Esophageal Cancer Icotinib Plus Radiotherapy Ups Survival in Elderly With Esophageal Cancer
Icotinib with concurrent radiotherapy (RT) boosts survival and may have other benefits compared to RT alone in elderly patients with unresectable esophageal squamous cell carcinoma, according to Chinese researchers.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - October 19, 2020 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Addition of Radiotherapy for DCIS Cuts Risk for Subsequent Cancer
FRIDAY, Oct. 16, 2020 -- For women with ductal carcinoma in situ (DCIS), the risk for developing subsequent ipsilateral in situ (iDCIS) and invasive breast cancer (iBC) is lower for those receiving breast-conserving surgery (BCS) and radiotherapy... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 16, 2020 Category: Pharmaceuticals Source Type: news

Oncotarget: Geriatric nutritional risk index - prognostic marker of esophageal carcinoma
(Impact Journals LLC) Oncotarget Volume 11, Issue 29 reported that In multivariate analyses, serum albumin, GNRI, pathological tumor-node-metastasis stage, and tumor differentiation were independent prognostic factors for CSS. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 16, 2020 Category: Cancer & Oncology Source Type: news